Procalcitonin in Sepsis by Rojas-Moreno, Christian & Regunath, Hariharan
January 15, 2016
Procalcitonin in Sepsis
medicine2.missouri.edu/jahm/procalcitonin-in-sepsis/
Procalcitonin in Sepsis
Christian Rojas-Moreno MD , Hariharan Regunath MD
 Department of Medicine – Division of Infectious Diseases, University of Missouri, Columbia,
MO 65212.
 Department of Medicine – Division of Pulmonary and Critical Care, University of Missouri,
Columbia, MO 65212.
Introduction:
Sepsis is defined as the confirmed or likely presence of infection in combination with systemic
manifestations of infection . Unfortunately, cultures may be negative and systemic
manifestations (also known as systemic inflammatory response syndrome or SIRS) can also
result from a noninfectious etiology. Because delays in diagnosis and treatment of sepsis
increase mortality, we need reliable diagnostic biomarkers to identify early sepsis .
Procalcitonin (PCT) has been studied over the past two decades as a potential marker for
bacterial infections.
PCT is the 166-amino-acid precursor of calcitonin that is produced by the C-cells of the thyroid
gland and is cleaved into calcitonin, katacalcin, and an N-terminal fragment. PCT levels are
undetectable (< 0.1 ng/ml) in otherwise healthy adults. In bacterial sepsis, PCT levels increase
rapidly secondary to its synthesis from almost all parenchymal tissues which lack the ability to
cleave PCT . In contrast, viral infections or noninfectious inflammatory reactions do not or
only result in a moderate increase in PCT levels in blood. Moreover, recovery from bacterial
infection with antibiotic therapy, resulted in a simultaneous decline in PCT levels . Hence, PCT
has been used as a diagnostic and prognostic biomarker in sepsis. Over the years, the role of
PCT has expanded to aid in antibiotic stewardship programs to curtail the use of unnecessary
antibiotics for noninfectious SIRS or viral infections .
Procalcitonin measurement:
PCT is detectable in blood within 2-4 hours of infection, peaks within 6-24 hours and can be
present for up to 7 days. The half-life is 22-26 h. All PCT assays are based on immunoassay
techniques . There are no studies precisely defining the optimum time for PCT measurement
and it is unclear whether trends or absolute levels should be used. The cutoffs that separated
patients with sepsis from those without sepsis have varied greatly between studies . Changes
in the cutoff values alter the sensitivity at the cost of specificity or vice versa. The figure below
shows a comment attached to a reported PCT value in our facility (VIDAS® B.R.A.H.M.S.
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PCT™, bioMérieux, Durham, NC).
Procalcitonin Figure 1
Figure 1: Comments attached to the procalcitonin (PCT) report in our institution.
Procalcitonin as a diagnostic biomarker:
Early administration of empiric or appropriate antibiotic therapy is indicated in sepsis. At the
same time, being able to hold or stop antibiotics in noninfectious SIRS is also important to
reduce antibiotic costs, side effects and bacterial resistance. Hence, it is important to
distinguish sepsis from noninfectious SIRS in the intensive care unit. The 2012 International
Guidelines for the Management of Severe Sepsis and Shock, clarify that PCT levels or other
biomarkers such as C-reactive protein (CRP) do not help to differentiate the acute
inflammation of sepsis from other causes of generalized inflammation  . However, the same
guidelines connote that low PCT levels can assist the decision to discontinue empiric
antibiotics in cases where sepsis was included in the initial differential diagnoses at admission,
but had no subsequent evidence for infection.
Several meta-analyses have investigated the accuracy of PCT for the diagnosis of sepsis, with
conflicting results. Uzzan et al. found that PCT represented a good biological diagnostic
marker for sepsis, severe sepsis, or septic shock in critically ill patients and PCT fared better
than CRP for identifying sepsis . In contrast, Tang et al. reported a low diagnostic
performance of PCT with both sensitivity and specificity being 71% (95% CI 67-76) . Major
limitations in both meta-analyses were non-inclusion of a heterogeneous patient population
and bias generated by the choice of definition for sepsis which does not have a universally
accepted gold standard definition to-date. Wacker et al. performed a meta-analysis with the
intention of addressing these limitations. Of the 3,244 critically ill patients, 1,863 (57%) had
sepsis and 1,381 (43%) had SIRS of noninfectious origin. Pooled sensitivity was 0.77 (95% CI
0.72-0.81) and specificity was 0.79 (95% CI 0.74-0.84). The area under the receiver operating
characteristic curve was 0.85 (95% CI 0.81-0.88). The authors concluded that PCT may be a
helpful marker for early diagnosis of sepsis in critically ill patients, particularly if used in the
context of medical history, physical examination, and microbiological assessment.
Procalcitonin as a prognostic biomarker:
In community-acquired pneumonia and ventilator-associated pneumonia, PCT was shown to
predict risk of death . Procalcitonin levels in the early stages of sepsis are significantly
lower among survivors versus non-survivors of sepsis . A study in adults admitted to intensive
care units with SIRS, reported that PCT level decreased significantly from day 1 to day 2 in
survivors but not in nonsurvivors, suggesting that serial measurements improve its accuracy
for mortality prediction . Liu et al. recently published a meta-analysis including 3,994 patients
and found that PCT non-clearance was associated with an increased risk of death in patients
with sepsis. Even in early studies on PCT, where patients were categorized into SIRS, sepsis,
severe sepsis and septic shock, PCT levels were more elevated in patients with severe sepsis
and septic shock .
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Procalcitonin in antibiotic stewardship:
Antibiotic stewardship programs (ASP) in several hospitals have included procalcitonin into
their algorithms in order to appropriately start or stop antibiotics. One study evaluated
usefulness of PCT for the initiation of antibiotic in intensive care unit patients but found it to be
not useful . A prospective randomized controlled trial compared a PCT-guided antibiotic
regimen to a standard antibiotic regimen in surgical intensive care patients; in the PCT group,
antibiotics were discontinued if clinical findings of infection improved and PCT levels
decreased to less than 1 ng/ml or had dropped to 25-35% of the initial value over three days if
the PCT level remains above 1 ng/mL. The duration of antibiotic therapy was significantly
shorter in the PCT group than in the control group (5.9 +/- 1.7 versus 7.9 +/- 0.5 days, P
<0.001) . One program was able to decrease antibiotic consumption by 21.2% a year after
implementation of a PCT-guided ASP ; however, mortality rate and length of stay remained
unchanged over the study period. Schuetz et al. proposed adapted algorithms based on 14
randomized controlled trials that investigated procalcitonin protocols for antibiotic treatment
decisions in adult patients with respiratory tract infections and sepsis from primary care,
emergency department, and intensive care unit settings . For example, for the intensive care
unit, the investigators proposed that antibiotics should be discouraged if the PCT was <0.5
ng/ml and strongly discouraged if the PCT was <0.25 ng/ml but this could be overruled if there
is clinical suspicion of infection. If antibiotics were started for suspected sepsis in the intensive
care unit, PCT levels can be monitored from initiation of antibiotic therapy, and if PCT levels
decline to <0.5 ng/ml or drop by 80%, cessation of antibiotics can be considered. They
concluded that PCT measurement appears to reduce antibiotic exposure without worsening
the mortality rate.
Conclusion:
PCT is not a perfect marker for a diagnosis of sepsis. Nevertheless, it could be very helpful in
addition to a thorough history, physical exam, appropriate laboratory tests and imaging.
Sensitivity and specificity varied according to the cutoffs used, but specificity increases as the
value rises. Persistent PCT elevation over days may prognosticate increasing severity of
illness and mortality. A value of less than < 0.5 ng/ml in a patient with SIRS without the
evidence of infection and negative cultures, can be used to support the clinician’s decision to
discontinue antibiotics. Clinical judgement is always required when using this biomarker.
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